Fundraising FoxY-Biologics
Daejeon, KR · Founded 2007 · 6 known investors
Find your way into Y-Biologics
Sign up to see every warm intro you have to Y-Biologics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Y-Biologics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Y-Biologics (와이바이오로직스) develops antibody-based drugs using its antibody discovery, fully human antibody library, and antibody engineering technologies, working through its own pipeline and partner collaborations. Its programs include next-generation immuno-oncology therapies such as Multi-AbKine, a multi antibody-cytokine fusion aimed at cancers resistant to existing immunotherapies, along with bispecific antibodies, VHH nanobodies, pH-sensitive antibodies, and ADC antibodies.
Also known as (주)와이바이오로직스 · Y-Biologics · 와이바이오로직스
Investors · 6
Company profile
researched Aug 2026Y-Biologics (와이바이오로직스) is a Korean company that positions itself as a developer of next-generation multi-antibody drugs. Its public materials emphasize continuous antibody drug research and development activity as the basis for accumulating antibody-specific technical capability.
As of June 2025 the company reported 48 employees, 121 patent applications filed and 62 patents registered, and it also tracks technology transfer deals and joint (open innovation) research and development collaborations as headline metrics. The company maintains a partner section describing collaborations, and publishes a news feed covering both its own announcements and broader oncology and pharmaceutical industry developments.
Traction
Company-reported figures as of June 2025 include 48 employees, 121 patent applications filed and 62 patents registered, alongside technology transfer and open innovation collaboration activity [0].
Latest developments
In July 2026 the company announced that the core antibody for an ADC drug candidate co-developed with Intocell secured a US patent, and reported a reorganization placing R&D leadership at the forefront of its board to accelerate clinical development [0].
▸Full profile — technology, geography
Technology
The company's public positioning centers on antibody research and development, including next-generation multi-antibody drug programs and antibody-drug conjugate (ADC) work; an antibody co-developed with Intocell for an ADC drug candidate obtained a US patent, announced in July 2026 [0].
Geography
Headquartered in South Korea; company communications are published in Korean [0].
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsCompany news item reporting a board reorganization placing R&D practitioners at the front to speed up clinical development.
The company announced that the key antibody used in an antibody-drug conjugate candidate developed jointly with Intocell obtained a US patent.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- ybiologics Venture Capitalybiologics.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Y-Biologics do?
- Korean biotech developing next-generation multi-antibody therapeutics, with 48 employees as of June 2025.
- Who are Y-Biologics's investors?
- Y-Biologics's investors include Aju IB Investment, DAYLI Partners, IMM Investment Japan, Kiwoom Investment, Magna Investment, Pearl Abyss Capital.
- Where is Y-Biologics headquartered?
- Y-Biologics is headquartered in Daejeon, KR.